Spacecom Confirms Control Transfer to Liron Karsin's Omega
Translated & summarized from Calcalist by baba
Spacecom confirmed Tuesday that control of the company is being transferred to Omega, owned by Liron Karsin, for NIS 48.5 million. The deal, which values Spacecom at NIS 154 million, requires court and Ministry of Communications approval. Omega, a private IT services firm, previously managed COVID-19 testing at Ben Gurion Airport and has since acquired a pharmaceutical wholesaler.
The story in 5 lines · by baba
- Spacecom confirmed control transfer to Liron Karsin's Omega for NIS 48.5 million.
- The deal values Spacecom at NIS 154 million, with shares sold at NIS 2.18 each.
- The transaction requires approval from the court and the Ministry of Communications.
- Omega previously managed COVID-19 testing at Ben Gurion Airport.
- Omega also acquired pharmaceutical wholesaler Carmel three and a half years ago.
Spacecom announced Tuesday that control of the company is set to transfer to Omega, owned by Liron Karsin, confirming a report from the previous day. The controlling shares, representing 31.4% of Spacecom's stock, will be sold to Omega for NIS 48.5 million, valuing the company at NIS 154 million. Each share will be sold for NIS 2.18, a significant increase from the NIS 1.63 trading price at the market's opening on Tuesday. The receiver for Eurocom Real Estate has requested court approval for the sale, having secured consent from the secured creditors, including Mizrahi Tefahot Bank, Menora Mivtachim, and Altshuler Shaham, to whom the shares are pledged. The transaction is contingent upon court approval and the Ministry of Communications' consent.
Omega, officially Omega Institute for Modern Teaching, is a private company providing computing services to the state. It gained prominence six years ago when it partnered with Rambam Health Care Campus to establish COVID-19 testing facilities at Ben Gurion Airport, serving millions of travelers until the pandemic subsided. Omega's prior attempt to enter the medical sector through a merger with the publicly traded Bio-View was unsuccessful due to a third party's takeover of Bio-View after the deal's approval but before its completion. Approximately three and a half years ago, Omega acquired Carmel, a pharmaceutical wholesaler, which was being sold as part of the Moriah Group's collapse. Carmel currently markets about a thousand drugs to major pharmacy chains.